HIT happens: Diagnosing and evaluating the patient with heparin-induced thrombocytopenia

Anesthesia and Analgesia

Volumn 107, Issue 2, 2008, Pages 356-358

  Greinacher, Andreas ^a   Levy, Jerrold H ^b,c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; THROMBOCYTE FACTOR 4; ANTICOAGULANT AGENT;

ANAPHYLAXIS; ANTICOAGULATION; CARDIOPULMONARY BYPASS; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL CIRCULATION; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIMB AMPUTATION; PATHOGENESIS; PRIORITY JOURNAL; THROMBOSIS; ANTIBODY PRODUCTION; CHEMICALLY INDUCED DISORDER; CHILD; IMMUNOLOGY; NEWBORN; NOTE; REOPERATION; THROMBOCYTOPENIA;

ANTIBODY FORMATION; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CHILD; HEPARIN; HUMANS; INFANT, NEWBORN; PLATELET FACTOR 4; REOPERATION; THROMBOCYTOPENIA;

EID: 49949098033     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e31817b65c2     Document Type: Editorial

References (23)

1. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:S64-S94
2. Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 2008;106:392-403
3. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:S311S-S337
4. Keeling D, Davidson S, Watson H. The management of heparininduced thrombocytopenia. Br J Haematol 2006;133:259-69
5. Levy JH, Tanaka KA, Hursting MJ. Reducing thrombotic complications in the perioperative setting: an update on heparininduced thrombocytopenia. Anesth Analg 2007;105:570-82
6. Frame JN. The heparin-induced thrombocytopenia task force model: implementing quality improvement and economic outcome initiatives. Semin Hematol 2005;42:S28-S35
7. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8
8. Everett BM, Yeh R, Foo SY, Criss D, Van Cott EM, Laposata M, Avery EG, Hoffman WD, Walker J, Torchiana D, Jang IK. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 2007;83:592-7
9. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-31
10. Bennett-Guerrero E, Slaughter TF, White WD, Welsby IJ, Greenberg CS, El-Moalem H, Ortel TL. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005;130:1567-72
11. Mullen MP, Wessel DL, Thomas KC, Gauvreau K, Neufeld EJ, McGowan FX, DiNardo JA. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg 2008;107:371-8
12. Dellaria SM, Greilich PE, Sarode R. Urgent cardiac surgery in a patient with a remote history of heparin-induced thrombocytopenia: the use of the anti-PF4/heparin ELISA confirmatory test. Anesth Analg 2008;107:379-81
13. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92
14. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002;122:37-42
15. Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-6
16. Kress DC, Aronson S, McDonald ML, Malik MI, Divgi AB, Tector AJ, Downey FX III, Anderson AJ, Stone M, Clancy C. Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg 2007;83:1737-43
17. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-51
18. Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 2006;81:36-44
19. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002;126:1415-23
20. Alberio L, Lammle B. More on: thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2005;3:1549
21. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007;5:1666-73
22. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-6
23. Greinacher A. Too many hits in HIT? Am J Hematol 2007;82: 1035-6